Table 3.
Some of larger published papers about hypo-fractionated stereotactic radiotherapy (HSRT) alone for large brain metastases
| Authors | N. pts | Total dose/n.frs | mLC mos | 1 yr b LC% | mOS mos | 1 yr b OS% | Toxicity % |
|---|---|---|---|---|---|---|---|
| Aoyama [14] | 87 | 35 Gy/4 | NR | 81 | 8.7 | 39 | 5 |
| Ernst-Stecken [15] | 51 | 35 Gy/5 | 7 | 76 % | 11 | NR | 2 |
| Fahrig [16] | 150 | 30–35 Gy/5 | NR | NR | 16 | 66 | 10 |
| 40 Gy/10 | 0 | ||||||
| 35 Gy/7 | |||||||
| Narayana [17] | 20 | 30 Gy/5 | NR | 70 | 8.5 | 64.5 | 2 |
| Kim [19] | 40 | 36 Gy/6 | NR | 69 | 8 | 34 | 5 |
| Ogura [20] | 39 | 35 Gy/5 | NR | 86.7 | 64.5 | 2 | |
| Minniti [23] | 135 | 36 Gy/3 | NR | 88 | 14.8 | 57 | 7 |
| 27 Gy/3 | |||||||
| Rajakesari [24] | 70 | 25 Gy/5 | 17 | 56 | 10.7 | NR | 4.3 |
| Croker [25]a | 61 | 24 Gy/3 | 9 | 69 | 21 | 60 | 7 |
Pts patients, frs fractions, mLC median local control, yr year, mOS median overall survival, mos months
aIncluding patients underwent surgery plus hypofractionated stereotactic radiosurgery (HSRS)
bActuarial